Regulus: First patient dosed in third cohort of Phase 1b MAD study of RGSL8429

Regulus Therapeutics announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. “After announcing the completed safety review of available data and the advancement to cohort three last month, we are excited to now be dosing our first patient in the third cohort,” said Jay Hagan, CEO of Regulus Therapeutics. “Our Phase 1b MAD clinical trial remains on track, and we look forward to sharing topline data from the second cohort of the study in the first quarter of 2024.”